Tags

Type your tag names separated by a space and hit enter

Neurocognitive effects of switching from methylphenidate-IR to OROS-methylphenidate in children with ADHD.
Hum Psychopharmacol. 2009 Mar; 24(2):95-102.HP

Abstract

OBJECTIVES

This study evaluated neurocognitive changes after switching from immediate release forms of methylphenidate (MPH-IR) to osmotic release oral system methylphenidate (OROS-MPH).

METHODS

102 children with attention-deficit/hyperactivity disorder (ADHD) participated in an open label, 28 day trial, performing neurocognitive test at baseline and at 28 days after the switch from MPH-IR to OROS-MPH.

RESULTS

There were significant improvements in the commission error and the reaction time of both visual and auditory continuous performance tests (CPTs) at 28 days after switching from MPH-IR to OROS-MPH. A positive correlation was observed between the improvement in parent/caregiver-rated IOWA Conners total score (Delta IOWA) and the reduction in commission error (r = 0.3, p = 0.001) and reduction in reaction time variability (r = 0.3, p = 0.006) of visual CPT. In a linear regression model, the change in parent/caregiver-rated IOWA Conners scale total scores were significant predictors of change in commission error (beta = 0.3, p = 0.005, CI = 0.4-2.3, adjusted R(2) = 0.12) and RT variability (beta = 0.3, p = 0.004, CI = 0.5-2.4, adjusted R(2) = 0.09) of visual CPT.

CONCLUSIONS

These data suggest that MPH-IR may be successfully switched to OROS-MPH treatment with associated improvements in neurocognitive performance. Large-scale controlled trials are needed to replicate these findings.

Authors+Show Affiliations

Department of Psychiatry, Division of Child and Adolescent Psychiatry, Institute of Human Behavioral Medicine, Seoul National University Hospital, Seoul, Korea.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

19226534

Citation

Kim, Yeni, et al. "Neurocognitive Effects of Switching From methylphenidate-IR to OROS-methylphenidate in Children With ADHD." Human Psychopharmacology, vol. 24, no. 2, 2009, pp. 95-102.
Kim Y, Shin MS, Kim JW, et al. Neurocognitive effects of switching from methylphenidate-IR to OROS-methylphenidate in children with ADHD. Hum Psychopharmacol. 2009;24(2):95-102.
Kim, Y., Shin, M. S., Kim, J. W., Yoo, H. J., Cho, S. C., & Kim, B. N. (2009). Neurocognitive effects of switching from methylphenidate-IR to OROS-methylphenidate in children with ADHD. Human Psychopharmacology, 24(2), 95-102. https://doi.org/10.1002/hup.1010
Kim Y, et al. Neurocognitive Effects of Switching From methylphenidate-IR to OROS-methylphenidate in Children With ADHD. Hum Psychopharmacol. 2009;24(2):95-102. PubMed PMID: 19226534.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Neurocognitive effects of switching from methylphenidate-IR to OROS-methylphenidate in children with ADHD. AU - Kim,Yeni, AU - Shin,Min-Sup, AU - Kim,Jae-Won, AU - Yoo,Hee-Jung, AU - Cho,Soo-Churl, AU - Kim,Boong-Nyun, PY - 2009/2/20/entrez PY - 2009/2/20/pubmed PY - 2009/4/9/medline SP - 95 EP - 102 JF - Human psychopharmacology JO - Hum Psychopharmacol VL - 24 IS - 2 N2 - OBJECTIVES: This study evaluated neurocognitive changes after switching from immediate release forms of methylphenidate (MPH-IR) to osmotic release oral system methylphenidate (OROS-MPH). METHODS: 102 children with attention-deficit/hyperactivity disorder (ADHD) participated in an open label, 28 day trial, performing neurocognitive test at baseline and at 28 days after the switch from MPH-IR to OROS-MPH. RESULTS: There were significant improvements in the commission error and the reaction time of both visual and auditory continuous performance tests (CPTs) at 28 days after switching from MPH-IR to OROS-MPH. A positive correlation was observed between the improvement in parent/caregiver-rated IOWA Conners total score (Delta IOWA) and the reduction in commission error (r = 0.3, p = 0.001) and reduction in reaction time variability (r = 0.3, p = 0.006) of visual CPT. In a linear regression model, the change in parent/caregiver-rated IOWA Conners scale total scores were significant predictors of change in commission error (beta = 0.3, p = 0.005, CI = 0.4-2.3, adjusted R(2) = 0.12) and RT variability (beta = 0.3, p = 0.004, CI = 0.5-2.4, adjusted R(2) = 0.09) of visual CPT. CONCLUSIONS: These data suggest that MPH-IR may be successfully switched to OROS-MPH treatment with associated improvements in neurocognitive performance. Large-scale controlled trials are needed to replicate these findings. SN - 1099-1077 UR - https://www.unboundmedicine.com/medline/citation/19226534/Neurocognitive_effects_of_switching_from_methylphenidate_IR_to_OROS_methylphenidate_in_children_with_ADHD_ L2 - https://doi.org/10.1002/hup.1010 DB - PRIME DP - Unbound Medicine ER -